WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors
|Childhood Central Nervous System Neoplasm Recurrent Childhood Medulloblastoma Recurrent Childhood Supratentorial Embryonal Tumor, Not Otherwise Specified Recurrent Malignant Solid Neoplasm Recurrent Neuroblastoma Recurrent Rhabdomyosarcoma||Drug: Irinotecan Hydrochloride Other: Laboratory Biomarker Analysis Other: Pharmacological Study Drug: WEE1 Inhibitor AZD1775||Phase 1 Phase 2|
|Study Design:||Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:||A Phase 1/2 Study of AZD1775 (MK-1775) in Combination With Oral Irinotecan in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors|
- Maximum tolerated dose (MTD) defined as the maximum doses of WEE1 inhibitor MK-1775 and irinotecan hydrochloride at which fewer than one-third of patients experience dose limiting toxicities when receiving this combination [ Time Frame: 21 days ]
- Pharmacokinetic (PK) parameters of WEE1 inhibitor MK-1775 in terms of systemic exposure [ Time Frame: Course 1 day 1 prior to the irinotecan infusion, prior to the MK-1775 dose, 4 hours after the dose of MK-1775 is given, and prior to the irinotecan dose on day 2 ]The PK parameters will be summarized with simple summary statistics, including means, medians, ranges, and standard deviations (if numbers and distribution permit).
- PK parameters of WEE1 inhibitor MK-1775 in terms of drug clearance [ Time Frame: Course 1 day 1 prior to the irinotecan infusion, prior to the MK-1775 dose, 4 hours after the dose of MK-1775 is given, and prior to the irinotecan dose on day 2 ]The PK parameters will be summarized with simple summary statistics, including means, medians, ranges, and standard deviations (if numbers and distribution permit).
- Change in phosphorylated-cyclin-dependent kinase 1 (p-CDK1) levels [ Time Frame: Baseline up to 1 year ]Decreased p-CDK1 indicating Wee1 inhibition by WEE1 inhibitor MK-1775 will be investigated. These analyses will be descriptive and exploratory and hypotheses generating in nature.
- Predictive biomarkers of WEE1 inhibitor MK-1775 sensitivity [ Time Frame: Up to 1 year ]These analyses will be descriptive and exploratory and hypotheses generating in nature.
- Response rate according to Response Evaluation Criteria in Solid Tumors [ Time Frame: Up to 1 year ]Response rates will be calculated as the percent of patients whose best response is a complete response (CR) or partial response (PR) and confidence intervals will be constructed according to the method of Chang. A responder is defined as a patient who achieves a best confirmed response of PR or CR on the study.
|Actual Study Start Date:||March 27, 2014|
|Estimated Primary Completion Date:||April 30, 2021 (Final data collection date for primary outcome measure)|
Experimental: Treatment (irinotecan hydrochloride, WEE1 inhibitor MK-1775)
Patients receive irinotecan hydrochloride PO and WEE1 inhibitor MK-1775 PO on days 1-5. Treatment repeats every 21 days for 18 courses in the absence of disease progression or unacceptable toxicity.
Drug: Irinotecan Hydrochloride
Other Names:Other: Laboratory Biomarker Analysis
Correlative studiesOther: Pharmacological Study
Correlative studiesDrug: WEE1 Inhibitor AZD1775
I. To estimate the maximum tolerated dose (MTD) and/or recommended Phase 2 dose of AZD1755 (MK-1775) administered on days 1 through 5 every 21 days, in combination with oral irinotecan (irinotecan hydrochloride), to children with recurrent or refractory solid tumors.
II. To define and describe the toxicities of AZD1755 (MK-1775) in combination with oral irinotecan administered on this schedule.
III. To characterize the pharmacokinetics of AZD1755 (MK-1775) in children with refractory cancer.
I. To preliminarily define the antitumor activity of AZD1755 (MK-1775) and irinotecan within the confines of a Phase 1 study.
II. To obtain initial Phase 2 efficacy data on the anti-tumor activity of AZD1755 (MK-1775) in combination with irinotecan administered to children with relapsed or refractory neuroblastoma, in children with relapsed or refractory medulloblastoma/CNS PNET (central nervous system primitive neuroectodermal tumor) and in children with relapsed or refractory rhabdomyosarcoma.
III. To investigate checkpoint over-ride by AZD1755 (MK-1775) via the mechanism-based pharmacodynamic (PD) biomarker of decreased cyclin-dependent kinase 1 (CDK1) phosphorylation in correlative and exploratory studies.
IV. To evaluate potential predictive biomarkers of AZD1755 (MK-1775) sensitivity, including v-myc avian myelocytomatosis viral oncogene homolog (MYC), v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog (MYCN), phosphorylated-WEE1 G2 checkpoint kinase (p-Wee1), enhancer of zeste homolog 2 (Drosophila) (EZH2) and gamma-H2A histone family, member gamma-H2AX in tumor tissues in correlative and exploratory studies.
OUTLINE: This is a phase I, dose-escalation followed by a phase II study.
Patients receive irinotecan hydrochloride orally (PO) and WEE1 inhibitor MK-1775 PO on days 1-5. Treatment repeats every 21 days for 18 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up periodically.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02095132
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02095132
Hide Study Locations
|United States, Alabama|
|Children's Hospital of Alabama||Recruiting|
|Birmingham, Alabama, United States, 35233|
|Contact: Alyssa T. Reddy 888-823-5923 email@example.com|
|Principal Investigator: Alyssa T. Reddy|
|United States, California|
|Children's Hospital Los Angeles||Recruiting|
|Los Angeles, California, United States, 90027|
|Contact: Leo Mascarenhas 888-823-5923 firstname.lastname@example.org|
|Principal Investigator: Leo Mascarenhas|
|Children's Hospital of Orange County||Recruiting|
|Orange, California, United States, 92868|
|Contact: Ivan I. Kirov 888-823-5923 email@example.com|
|Principal Investigator: Ivan I. Kirov|
|UCSF Medical Center-Parnassus||Suspended|
|San Francisco, California, United States, 94143|
|UCSF Medical Center-Mission Bay||Recruiting|
|San Francisco, California, United States, 94158|
|Contact: Kieuhoa T. Vo 877-827-3222|
|Principal Investigator: Kieuhoa T. Vo|
|United States, Colorado|
|Children's Hospital Colorado||Recruiting|
|Aurora, Colorado, United States, 80045|
|Contact: Margaret E. Macy 888-823-5923 firstname.lastname@example.org|
|Principal Investigator: Margaret E. Macy|
|United States, District of Columbia|
|Children's National Medical Center||Recruiting|
|Washington, District of Columbia, United States, 20010|
|Contact: Jeffrey S. Dome 888-823-5923 email@example.com|
|Principal Investigator: Jeffrey S. Dome|
|United States, Georgia|
|Children's Healthcare of Atlanta - Egleston||Recruiting|
|Atlanta, Georgia, United States, 30322|
|Contact: William T. Cash 888-823-5923 firstname.lastname@example.org|
|Principal Investigator: William T. Cash|
|United States, Illinois|
|Lurie Children's Hospital-Chicago||Recruiting|
|Chicago, Illinois, United States, 60611|
|Contact: Stewart Goldman 888-823-5923 email@example.com|
|Principal Investigator: Stewart Goldman|
|United States, Indiana|
|Riley Hospital for Children||Recruiting|
|Indianapolis, Indiana, United States, 46202|
|Contact: James M. Croop 800-248-1199|
|Principal Investigator: James M. Croop|
|United States, Massachusetts|
|Dana-Farber Cancer Institute||Recruiting|
|Boston, Massachusetts, United States, 02215|
|Contact: Steven G. DuBois 877-827-3222|
|Principal Investigator: Steven G. DuBois|
|United States, Michigan|
|C S Mott Children's Hospital||Recruiting|
|Ann Arbor, Michigan, United States, 48109|
|Contact: Rajen Mody 888-823-5923 firstname.lastname@example.org|
|Principal Investigator: Rajen Mody|
|United States, Minnesota|
|University of Minnesota/Masonic Cancer Center||Recruiting|
|Minneapolis, Minnesota, United States, 55455|
|Contact: Emily G. Greengard 888-823-5923 email@example.com|
|Principal Investigator: Emily G. Greengard|
|United States, Missouri|
|Washington University School of Medicine||Recruiting|
|Saint Louis, Missouri, United States, 63110|
|Contact: Robert J. Hayashi 800-600-3606 firstname.lastname@example.org|
|Principal Investigator: Robert J. Hayashi|
|United States, New York|
|Columbia University/Herbert Irving Cancer Center||Suspended|
|New York, New York, United States, 10032|
|United States, Ohio|
|Cincinnati Children's Hospital Medical Center||Recruiting|
|Cincinnati, Ohio, United States, 45229|
|Contact: James I. Geller 888-823-5923 email@example.com|
|Principal Investigator: James I. Geller|
|United States, Oregon|
|Oregon Health and Science University||Recruiting|
|Portland, Oregon, United States, 97239|
|Contact: Suman Malempati 503-494-1080 firstname.lastname@example.org|
|Principal Investigator: Suman Malempati|
|United States, Pennsylvania|
|Children's Hospital of Philadelphia||Recruiting|
|Philadelphia, Pennsylvania, United States, 19104|
|Contact: Elizabeth Fox 800-411-1222|
|Principal Investigator: Elizabeth Fox|
|Children's Hospital of Pittsburgh of UPMC||Recruiting|
|Pittsburgh, Pennsylvania, United States, 15224|
|Contact: Jean M. Tersak 888-823-5923 email@example.com|
|Principal Investigator: Jean M. Tersak|
|United States, Tennessee|
|St. Jude Children's Research Hospital||Recruiting|
|Memphis, Tennessee, United States, 38105|
|Contact: Michael W. Bishop 888-823-5923 firstname.lastname@example.org|
|Principal Investigator: Michael W. Bishop|
|United States, Texas|
|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center||Recruiting|
|Houston, Texas, United States, 77030|
|Contact: Jodi Muscal 713-798-1354 email@example.com|
|Principal Investigator: Jodi Muscal|
|United States, Washington|
|Seattle Children's Hospital||Suspended|
|Seattle, Washington, United States, 98105|
|United States, Wisconsin|
|Children's Hospital of Wisconsin||Suspended|
|Milwaukee, Wisconsin, United States, 53226|
|Hospital for Sick Children||Suspended|
|Toronto, Ontario, Canada, M5G 1X8|
|Principal Investigator:||Kristina Cole||COG Phase I Consortium|